Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
43 hedge funds and large institutions have $77.9M invested in Adaptimmune Therapeutics in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 13 closing their positions.
0.51% less ownership
Funds ownership: 10.84% → 10.32% (-0.51%)
12% less funds holding
Funds holding: 49 → 43 (-6)
24% less capital invested
Capital invested by funds: $103M → $77.9M (-$25M)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$625K |
| 2 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$381K |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
+$160K |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$131K |
| 5 |
HF
HRT Financial
New York
|
+$47.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.61M |
| 2 |
BlackRock
New York
|
-$1.25M |
| 3 |
Man Group
London,
United Kingdom
|
-$1.03M |
| 4 |
Millennium Management
New York
|
-$449K |
| 5 |
Morgan Stanley
New York
|
-$403K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Wells Fargo
San Francisco,
California
| – | -$587 | -550 | -69% |
|
ADAP Hedge Fund Activity: Q4 2019 in Review
43 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2019, worth a combined $77.9M — down 24% from $103M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ADAP and 7 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $625K. The largest seller was Wellington Management Group, cutting an estimated $1.61M.
- 43 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2019, down from 49 in Q3 2019.
- Funds reported $77.9M of Adaptimmune Therapeutics stock for Q4 2019, down 24% quarter-over-quarter.
- 7 funds opened new Adaptimmune Therapeutics positions in Q4 2019 and 13 closed out, a net change of -6 holders.
- The largest Adaptimmune Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $625K added.
- The largest Adaptimmune Therapeutics seller in Q4 2019 was Wellington Management Group, an estimated $1.61M sold.
Based on aggregated 13F filings for Q4 2019.